FDA approves VYALEV for adults living with advanced parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
We now rank 3rd in pharmaceutical production by volume and 14th by value
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Poor oral health (periodontal disease) impacts nearly 51% of Indians
He holds a Master’s in Management from the National University of Singapore
AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Subscribe To Our Newsletter & Stay Updated